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Reply to Rizzatti et al.
We would like to thank Dr. Rizzatti and
colleagues for their interest in our paper
entitled “Endoscopic ultrasound and
fine-needle aspiration for the detection
of residual nodal disease after neoadju-
vant chemoradiotherapy for esophageal
cancer” [1].
In their letter to the editor, Dr. Rizzatti
and colleagues stress the need for stan-
dardization of restaging strategies to im-
prove the detection rate of residual no-
dal disease after neoadjuvant chemora-
diotherapy for esophageal cancer. The
authors suggest a systematic approach
in which sampling of an adjacent lymph
node (LN) station is only performed in
the absence of a positive smear from the
previously sampled LN station – compar-
able to an algorithm that was previously
published on initial staging of esopha-
geal cancer [2].
We agree that a change of diagnostic
strategy is needed in this clinical setting.
After neoadjuvant chemoradiotherapy,
residual nodal disease cannot reliably be
ruled out based on endoscopic ultra-
sound (EUS) features alone, necessitat-
ing concomitant fine-needle aspiration
(FNA) sampling, preferably in the pres-
ence of rapid on-site cytopathological
evaluation (ROSE). However, we believe
that, even in the presence of ROSE, ade-
quate sampling of LNs will remain chal-
lenging owing to neoadjuvant chemora-
diotherapy-induced fibrosis and the focal
distribution of vital tumor cells [3]. In-
deed, development of a restaging algo-
rithm may be an important step forward.
Ideally, such a restaging algorithm
should take into account LN distribution
based on both patient and disease char-
acteristics, and enable targeting of the
LNs that are most likely to be affected.
The results of the ongoing TIGER study –
a study on the LN distribution in resect-
able esophageal cancer after neoadju-
vant therapy – may serve to develop
such tool [4].
Competing interests
The authors declare that they have no con-
flict of interest.
The authors
Ruben D. van der Bogt1, Berend J. van der
Wilk2, Jan J. B. van Lanschot2, Manon C. W.
Spaander1
1 Department of Gastroenterology and
Hepatology, Erasmus MC University Medical
Center, Rotterdam, The Netherlands
2 Department of Surgery, Erasmus MC
University Medical Center, Rotterdam,
The Netherlands
Corresponding author
M. C. W. Spaander, MD
Erasmus MC University Medical Center,
Doctor Molewaterplein 40, 3015 GD,
Rotterdam, The Netherlands
v.spaander@erasmusmc.nl
References
[1] van der Bogt RD, van der Wilk BJ, Poley JW et
al. Endoscopic ultrasound and fine-needle
aspiration for the detection of residual nodal
disease after neoadjuvant chemoradiother-
apy for esophageal cancer. Endoscopy 2019:
doi:10.1055/a-1065-1759
[2] Vazquez-Sequeiros E, Wiersema MJ, Clain JE
et al. Impact of lymph node staging on
therapy of esophageal carcinoma. Gastro-
enterology 2003; 125: 1626–1635
[3] Zuccaro GJr., Rice TW, Goldblum J et al.
Endoscopic ultrasound cannot determine
suitability for esophagectomy after aggres-
sive chemoradiotherapy for esophageal
cancer. Am J Gastroenterol 1999; 94: 906–
912
[4] Hagens ERC, van Berge Henegouwen MI, van
Sandick JW et al. Distribution of lymph node
metastases in esophageal carcinoma [TIGER
study]: study protocol of a multinational
observational study. BMC Cancer 2019; 19:
662
Bibliography
DOI https://doi.org/10.1055/a-1114-2608
Endoscopy 2020; 52: 317
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X
Letter to the editor
van der Bogt Ruben D et al. Reply to Rizzatti et al.… Endoscopy 2020; 52: 317 317
D
ow
nl
oa
de
d 
by
: E
ra
sm
us
 U
ni
ve
rs
ite
it 
Ro
tte
rd
am
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
